Posts by: Joana Fernandes, PhD

Joana Fernandes, PhD

Joana brings more than 8 years of academic research and experience as well as Scientific writing and editing to her role as a Science and Research writer. She also served as a Postdoctoral Researcher at the Center for Neuroscience and Cell Biology in Coimbra, Portugal, where she also received her PhD in Health Science and Technologies, with a specialty in Molecular and Cellular Biology.

May 16, 2017

Alunbrig Shows Promise in Certain Advanced NSCLC Patients with ALK Mutations, Study Reports

News

Takeda’s Alunbrig (brigatinib) has shown promise in treating ALK-positive metastatic non-small cell lung cancer (NSCLC) patients who either progressed with — or could not tolerate treatment with — Xalkori (crizotinib). ... Read more

May 11, 2017May 11, 2017

Clinical Trial to Test Biocept’s Target Selector Platform as Diagnosis, Monitoring Tool for Lung Cancer

News

Biocept and the Addario Lung Cancer Medical Institute (ALCMI) will collaborate on a clinical study assessing the efficacy of Biocept’s Target Selector platform to detect circulating biomarkers in patients with lung ... Read more

January 26, 2017

Advanced NSCLC Patients Live Longer When Treated, but Proportion of Untreated Patients Rising

News

Patients with advanced non-small cell lung cancer (NSCLC) who receive treatment live longer than those who remain untreated, but the proportion of NSCLC patients with advanced disease who don’t receive treatment ... Read more

September 20, 2016September 20, 2016

Lung Cancer Imaging Combo May Identify ALK Fusions Responsive to Xalkori

News

Combining two biochemical techniques may help identify patients with non-small cell lung cancer (NSCLC) with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements that respond to treatment with Xalkori ... Read more